{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:55:05Z","timestamp":1791186905983,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>A fraction of tumor cells can survive therapy without acquiring stable resistance mutations and enter a drug-tolerant persister (DTP) state. After drug withdrawal, these cells may resume proliferation and regain drug sensitivity, retain phenotypic features that alter survival or death upon retreatment, or continue to evolve toward stable resistance. The DTP designation describes survival under therapeutic pressure but does not establish whether the associated state persists after treatment ends. The term post-treatment cellular memory is used here operationally for a treatment-associated state that remains detectable after adequate drug washout and can influence a later response. Evidence can be evaluated across three experimental dimensions: persistence after withdrawal, maintenance across subsequent cell divisions or clonal descendants, and a functional consequence upon re-exposure. These dimensions indicate different strengths of support rather than mandatory diagnostic criteria. The review therefore organizes representative studies by what was measured after withdrawal rather than by DTP markers or mechanisms alone. Recent work indicates that AP-1 can contribute to encoding treatment-associated transcriptional states and that CBP\/p300 activity can help maintain an established reporter state, including after drug withdrawal; however, molecular persistence does not substitute for demonstrating altered function upon rechallenge with the original agent. Chromatin remodeling, transcriptional state transitions, antioxidant metabolism, autophagy, organelle homeostasis, and lineage plasticity may prolong residual-cell survival. Their biological consequences differ: some states decay after withdrawal, some create time-limited vulnerabilities to ferroptosis or to therapeutic targeting of anti-apoptotic dependencies, and others extend the interval during which genetic resistance can emerge. Lineage tracing, single-cell multi-omics, withdrawal-rechallenge experiments, and longitudinal sampling of minimal residual disease can help distinguish transient stress responses from persistent post-treatment states. These observations provide a rationale for testing whether treatment sequence and interventions during residual disease can be matched to the reversibility and vulnerabilities of residual states.<\/jats:p>","DOI":"10.3389\/fphar.2026.1966584","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:25:17Z","timestamp":1791185117000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular memory after cancer therapy: persistence after drug withdrawal, maintenance across cell divisions, and responses to rechallenge"],"prefix":"10.3389","volume":"17","author":[{"given":"Chengyan","family":"Shi","sequence":"first","affiliation":[{"name":"The Second Department of Oncology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikun","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Second Department of Oncology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[{"name":"The Second Department of Oncology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/0008-5472.CAN-25-0995","article-title":"Characterization of drug-tolerant persister cells in triple-negative breast cancer identifies a shared persistence program across treatments and patients","author":"Baudre","year":"2025","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/cancers13112666","article-title":"Emerging insights into targeted therapy-tolerant persister cells in cancer","volume":"13","author":"Cabanos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.xcrm.2024.101471","article-title":"Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41418-025-01656-8","article-title":"Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms","volume":"33","author":"Davern","year":"2026","journal-title":"Cell Death Differ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"eaav0936","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/2767-9764.Crc-24-0442","article-title":"APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during EGFR inhibitor resistance in lung cancer","volume":"5","author":"Garcia","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"10905","DOI":"10.1038\/s41467-025-65888-5","article-title":"Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma","volume":"16","author":"Joun","year":"2025","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/0008-5472.Can-20-2811","article-title":"Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer","volume":"81","author":"Kashima","year":"2021","journal-title":"Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/cas.14316","article-title":"ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer","volume":"111","author":"Kawakami","year":"2020","journal-title":"Cancer Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70888","DOI":"10.1002\/mco2.70888","article-title":"CCL20 released by drug-tolerant persisters impairs immunotherapy in EGFR-mutant lung adenocarcinoma","volume":"7","author":"Kwok","year":"2026","journal-title":"MedComm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1612089","DOI":"10.3389\/fphar.2025.1612089","article-title":"Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12943-026-02622-9","article-title":"Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance","volume":"25","author":"Li","year":"","journal-title":"Mol. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1038\/s41467-026-70862-w","article-title":"AP-1 mediates cellular adaptation and memory formation","volume":"17","author":"Li","year":"","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"113771","DOI":"10.1016\/j.celrep.2024.113771","article-title":"Transcription factor ZNF263 enhances EGFR-Targeted therapeutic response and reduces residual disease in lung adenocarcinoma","volume":"43","author":"Liang","year":"2024","journal-title":"Cell Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40164-024-00509-3","article-title":"Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence","volume":"13","author":"Liu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1158\/0008-5472.Can-25-0433","article-title":"Transfer of damaged mitochondria from cancer cells to cancer-associated fibroblasts promotes tyrosine kinase inhibitor tolerance in EGFR-mutant lung cancer","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1771061","DOI":"10.3389\/fonc.2026.1771061","article-title":"Drug-tolerant persister cells in cancer: a scoping review of definitions, models, and molecular mechanisms","volume":"16","author":"Lopez-Gonzalez","year":"2026","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcdb.2023.11.003","article-title":"Persister cell plasticity in tumour drug resistance","volume":"156","author":"Mcdonald","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","article-title":"Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model","volume":"18","author":"Moghal","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s42003-024-06190-w","article-title":"Genome-wide CRISPR screens identify the YAP\/TEAD axis as a driver of persister cells in EGFR mutant lung cancer","volume":"7","author":"Pfeifer","year":"2024","journal-title":"Commun. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1038\/ncomms3467","article-title":"Non-darwinian dynamics in therapy-induced cancer drug resistance","volume":"4","author":"Pisco","year":"2013","journal-title":"Nat. Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41467-024-54728-7","article-title":"Early tolerance and late persistence as alternative drug responses in cancer","volume":"16","author":"Punzi","year":"2025","journal-title":"Nat. Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e10141","DOI":"10.15252\/msb.202010141","article-title":"Metabolic memory underlying minimal residual disease in breast cancer","volume":"17","author":"Radic Shechter","year":"2021","journal-title":"Mol. Syst. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in melanoma","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","article-title":"Targeting therapy-persistent residual disease","volume":"5","author":"Sun","year":"2024","journal-title":"Nat. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/2767-9764.Crc-24-0389","article-title":"Targeting PRMT1 reduces cancer persistence and tumor relapse in EGFR- and KRAS-mutant lung cancer","volume":"5","author":"Sun","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-Mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/0008-5472.Can-20-1488","article-title":"Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.18632\/aging.205409","article-title":"Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis","volume":"16","author":"Wu","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13073-026-01643-9","article-title":"Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple-negative breast cancer","volume":"18","author":"Zhang","year":"2026","journal-title":"Genome Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1966584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:25:18Z","timestamp":1791185118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1966584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":41,"alternative-id":["10.3389\/fphar.2026.1966584"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1966584","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1966584"}}